Received CE marking for the PCI 652nm medical laser

Oslo, 2 January 2012 - PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that it has received CE marking for its PCI 652nm laser as a medical device. PCI Biotech is approved as manufacturer and distributor of the laser. The approvals have been issued by the notifying body NEMKO, Norway.

The PCI 652nm laser will be used in the Phase II study of Amphinex® in head and neck cancer patients.